Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Alligator Bioscience Virtual R&D Day - August 27, 2020

Lund, Sweden, August 25, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) invites to a virtual R&D Day on August 27 at 2:00 p.m. – 3:00 p.m., in which CEO Per Norlén and COO Malin Carlsson will give an update on the status and latest development steps in the company's clinical pipeline - focusing on the drug candidates mitazalimab, ATOR-1015 and ATOR-1017. Guest speaker, Professor Ignacio Melero at University of Navarra, will give his view on 4-1BB, the target for ATOR-1017. Program (approximate times): 2:00 p.m.        Company introduction and clinical development update ATOR-

Finnair starts co-operation negotiations on plans to reduce 1 000 jobs due to COVID-19 impacts and travel restrictions; long-term temporary layoffs continue for thousands of Finnair employees

Finnair starts co-operation negotiations on its plan to reduce up to 1,000 jobs, to make other structural changes and to implement additional temporary layoffs due to the impacts of the corona pandemic. The co-operation negotiations concern approximately 2,800 employees working at Finnair in Finland, and similar processes are conducted in Finnair’s units abroad. Finnair employs a total of approximately 6,700 employees, of whom 6,200 are based in Finland. Almost all of Finnair’s employees in Finland have been temporary laid off for a part of the spring and summer. In addition to the planned

Finnair increases its savings target to approximately 100 million euros of permanent cost base reductions by 2022 onwards, superseding the previously announced target

Finnair Plc         Stock Exchange Release           25 August 2020 at 12.00 p.m. EEST On 20 May 2020, Finnair announced that it was targeting nearly 80 million euros in permanent cost base reductions by 2022, compared to 2019 levels.  After a thorough review of the sources for these potential savings, and in recognition that certain elements of the COVID-19 impact, such as remote working and its effect on business travel, are likely to be longer-term in nature, Finnair has increased its savings target by 20 million euros, increasing its initial expectations for a permanent reduction in

Alligator Bioscience presents the clinical project portfolio at Virtual R&D Day August 27, 2020

Lund, Sweden, August 25, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) will give status updates and details on the recent clinical development plans for the clinical drug candidates mitazalimab, ATOR-1015 and ATOR-1017 on a virtual R&D Day on August 27. “These clinical plans provide an excellent opportunity for Alligator to have two or even three competitive cancer therapeutics in clinical efficacy studies by the end of 2021”, commented Per Norlén, CEO of Alligator Bioscience. Mitazalimab is Alligator’s most advanced immunotherapy candidate intended for the treatment of

Scandinavian ChemoTech has been invited to participate in two prestigious events

Scandinavian ChemoTech has been invited to participate in both the Life Science Intelligence "LSI" Emerging Medtech Summit in California and the EU Gateway - Business Avenues in Singapore and Indonesia.LSI Emerging Medtech Summit is an event that brings together the best strategists, investors and innovators in the Med Tech industry. The summit will take place at the Ritz - Carlton in Laguna Niguel California on February 17 - 20, 2021 and is a 3-day event where ChemoTech and other medical technology companies will present their innovations to some of the largest medical technology players

KEBNI IS NOW TRADING ON NASDAQ FIRST NORTH GROWTH MARKET

KebNi AB (publ) ("KebNi" or the "Company") has today commenced trading on Nasdaq First North Growth Market.Today is the first day of trading for KebNi on Nasdaq First North Growth Market. "We are proud to welcome KebNi to Nasdaq First North Growth Market, Europe's leading market for small- and medium sized companies," said Adam Kostyál, Head of European Listings at Nasdaq. "KebNi is a leader within the increasingly important satellite communications industry and we look forward to supporting the company in its continued growth journey." "At KebNi we are excited to achieve another key

Invent Medic Sweden AB - Q2

Continued sales growth despite Covid-19 shutdowns in the UK and Germany FIRST HALF OF THE YEAR (January-June) · The company’s sales amounted to 873 (218) KSEK. · Operating costs amounted to 8,300 (6,333) KSEK. · Result before and after tax amounted to -7,545 (-6,116) KSEK. · Result per share amounted to -0.57 (-0.59) SEK. · Cash and cash equivalents at the end of the period amounted to 19,677(6,572 ) KSEK. SECOND QUARTER (April-June 2020) · The company’s sales amounted to 471 (101)  KSEK · Operating costs amounted to 4,266 (3,243) KSEK. · Result before and

The last exercise period of Brighter TO4 starts today

August 25 to September 8, 2020 is the last exercise period of Brighter TO4 during which holders of these warrants can subscribe for shares. One warrant gives the right to subscribe for one share at the subscription price of SEK 2. The TO4 warrants will after this exercise period become worthless and the holder will no longer have any right to subscribe for the shares. Holders of TO4 warrants who have their warrants registered in custody at a bank or broker shall contact their bank or broker if they want to exercise the warrants and subscribe for the corresponding shares. Exercise of

Ahlstrom-Munksjö enhances its high protection medical fabric portfolio with the addition of TrustShield™ Biological

AHLSTROM-MUNKSJÖ OYJ, PRESS RELEASE, August 25, 2020 at 11:00 EEST Ahlstrom-Munksjö announces the launch of TrustShield™ Biological, a personal protective apparel medical fabric designed to shield against hazardous pathogens. The TrustShield™ product portfolio offers a range of medical fabrics designed to provide superior protection in the operating room, clinical and laboratory environments. TrustShield™ fabrics are laser resistant, protect against chemical permeation, and are highly absorbent. They can be easily converted into medical grade gowns or drapes. TrustShield™

Attractive locations at Logistics Position Sunnanå outside Malmö – Catena welcomes more tenants

At Logistics Position Sunnanå, the level of activity continues to rise, with Scandinavian Cosmetics, Rechon Life Science and Padel Crew now moving into the last of the vacant premises in Catena’s recently constructed multi-tenant warehouse.25 August 2020, 10:00 a.m. CET With its excellent location for logistics, just outside Malmö and adjacent to the E6 and E20 motorways, Logistics Position Sunnanå has become a hub for transport and goods flows. There is considerable interest in setting up operations at the site and three more tenants are moving into the multi-tenant warehouse recently

Janes welcomes Christopher Light as Chief Financial Officer

The trusted global agency for open-source defence intelligence today welcomes Christopher Light to lead financial operations globallyLONDON – Janes  announced today the appointment of Christopher Light as Chief Financial Officer. Light will lead financial and legal operations for the company as they continue their evolution into a standalone enterprise “I’m excited to be joining Janes, the trusted global agency for open-source defence intelligence: an impressive brand and a talented team,” said Light. “I’m very much looking forward to the opportunity to

Citi Launches Direct Custody and Clearing Services in Finland

Launch expands Citi’s proprietary custody network to cover all Nordic countries and to become the only international bank to offer a pan-Nordic service. Helsinki, London – Citi will begin offering Direct Custody & Clearing (DCC) services in Finland, starting in August. This new offering expands Citi’s proprietary DCC network to cover the whole Nordic region, making Citi the only international bank to offer a pan-Nordic service.Citi DCC plays an integral role in the capital markets by providing clearing and settlement services for the trading and investing activities of broker dealers as

IRRAS Granted Sixth Patent for Hummingbird ICP Monitoring Product Line from United States Patent and Trademark Office (USPTO)

Stockholm, August 25, 2020 – IRRAS AB, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced the issuance of U.S. Patent No. 10,687,720 B2 for “Automatic Air Management System.” “The air management system that is protected by this newest patent drives the innovation that Hummingbird brings to the ICP monitoring space,” added Will Martin, President and Chief Commercial Officer of IRRAS. “Hummingbird uses this air system to calculate a patient’s intracranial pressure and provides the most accurate ICP

CEO’s address to Sectra AB’s 2020 Annual General Meeting published on the company’s website

Linköping, Sweden – August 25, 2020 – President and CEO Torbjörn Kronander’s pre-recorded address to the 2020 Annual General Meeting of the international medical imaging IT and cybersecurity company Sectra  (STO: SECT B) is now available on the company’s website.Watch the pre-recorded speech and responses to questions put forth by the company’s shareholders (in Swedish): investor.sectra.com/agm2020 Sectra’s Annual General Meeting (AGM) and financial report calendar  · September 2, 2020: Last day to vote in advance and register for the AGM · September

Finnish children get to participate in the evaluation of their early childhood education and care

Finnish children have a very positive attitude towards early childhood education and care (ECEC), according to new research from the University of Eastern Finland. Published in Early Child Development and Care this August, the study explored children’s negative experiences of early childhood education and care. The researchers have published an article on children’s positive experiences already earlier. “Studying children’s experiences of, and their participation in, early childhood education and care is very topical in Finland right now, since the country’s new ECEC legislation from

Zengun collaborates with Vectura on Forskaren

Zengun has signed an agreement with Vectura Fastigheter for designing and planning construction of the new Forskaren building in Hagastaden, Stockholm. Both parties aim for the collaboration to continue through the actual construction. The new building, which will become a new innovation centre for life science is expected to be occupation ready by the end of 2023.  Forskaren will contribute to a world-class science city by creating a creative meeting place for talent and innovation in life science. The premises will provide 24,000 square metres of flexible offices, shared space and the

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

Announcement no. 26 - 25 August 2020 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, Motortramp A/S continuously sells shares pro rata and the market is to be informed accordingly – see the attached file. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information: Martin Badsted, CFO, tel.: +45 3315 0451Anne-Louise Dam-Rasmussen, Head of Communications, tel.: +45 3273 0624

Vekka Group’s biogas-powered buses introduced in Hämeenlinna, Finland – Annual public transport emissions to be reduced by almost 500 tonnes

Six new biogas buses will be introduced in public transport in Hämeenlinna, Finland. The new Vekka Group buses will help reduce the city’s public transport emissions by almost 500 tonnes per year. The buses support the City of Hämeenlinna objective of increasing the use of sustainable transport and alternative fuels.The six new biogas-powered buses of Vekka Group Oy (Hämeenlinnan bussiliikenne) will start service in Hämeenlinna at the end of August 2020. Supplied by Scania Finland, the buses will operate in the city’s public transport services 1, 3 and 11, the contract for which was awarded

Shape Robotics announces its Half-Year Interim Report for January – June 2020

Company Announcement No. 10 - 2020Copenhagen, August 25[th], 2020This announcement is a summary and should be read in conjunction with Shape Robotics’ Interim Report for 1H, 2020 published on 25th of August 2020. The report for 1H 2020 will be available on the company’s website  and on this link . Business highlights in 1H, 2020The results from the first half year of 2020, are in line with the expectations communicated

Shopping centre Lippulaiva to become a pioneer of sustainable energy solutions – Citycon to participate in the EU’s sustainable energy project SPARCS

CITYCON OYJ   Press Release 25 August 2020Shopping centre Lippulaiva, due to be opened in spring 2022, will become the flagship of local energy production. The largest geothermal heating and cooling facility for a commercial building in Europe is being built under the shopping centre, and it will generate carbon-free energy to meet almost the entire heating and cooling needs of the shopping centre. The facility and several other sustainable energy solutions make it possible for Lippulaiva to participate in the EU’s SPARCS project, which aims to promote energy efficiency and electric-powered

Interim Report January - June 2020

APRIL 1[st] – JUN 30[th ]2020 ·Net sales amounted to EUR 4 889 thousand (5 569), a 12.2 percent decrease · EBITDA of EUR 183 thousand (52) and EBITDA margin of 3.7 percent (0.9) · EBIT of EUR 87 thousand (-40) and EBIT margin of 1.8 percent (-0.7) · Net earnings after tax of negative EUR 264 thousand (-801) · Net earnings after tax, adjusted for non-recognized FX gains, of negative EUR 146 thousand  JAN 1[st] – JUN 30[th ]2020 ·Net sales amounted to EUR 9 770 thousand (11 152), a 12.4 percent decrease · EBITDA of EUR 187 thousand (-37) and EBITDA margin

Idogen AB Interim report

January 1 – June 30, 2020Second quarter (April-June 2020)• Other operating income amounted to KSEK 2,782 (1,141)• Operating loss was KSEK -7,292 (-11,307 of which impairment loss on patents amounted to KSEK -4,573) KSEK• Loss for the period totalled -7,976 (-11,213) KSEK• Cash flow from operating activities was KSEK -9,003 (-6,531)• Loss per share was SEK -0.87 (-2.31)Period (January-June 2020)• Other operating income amounted to KSEK 4,195 (1,994)• Operating loss was KSEK -13,952 (-18,069)• Loss for the period totalled KSEK -14,197 (-17,856)• Cash flow from operating

Interim Report Q2, 2020

Second quarter 2020 All figures for 2020 and 2019 refer to the Group.Other operating income amounted to kSEK 872 (663)   · Result after taxes amounted to kSEK -4,810 (-4,149)   · Basic and diluted earnings per share: SEK -0.05 (-0.05) · The cash flow from operating activities was kSEK -5,775 (-3,547) First half of 2020 · Other operating income amounted to kSEK 2,057 (1,313). · Result after taxes amounted to kSEK -8,594 (-6,925)   · Basic and diluted earnings per share: SEK -0.10 (-0.08) · The cash flow from operating activities was kSEK -5,342 (-3,576) ·

There are no items matching the current filter
There are no more items matching the current filter
Back to top